Treating cardiac allograft rejection: present approach--analysis of 100 consecutive patients.
In addition to rejection, complications of rejection prophylaxis and treatment are major causes of mortality and morbidity during the first year after heart transplantation. To decrease complications related to antirejection treatment, our present approach is to assess each rejection episode individually and to adjust treatment accordingly. This article presents the analysis of rejection in the last 100 patients who underwent heart transplantation at our institution.
Radovancevic
B
B
Division of Cardiovascular Surgery, Texas Heart Institute, Houston 77225-0345.
Birovljev
S
S
Frazier
O H
OH
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006084:Graft Rejection / Q000187:drug effects*; D016027:Heart Transplantation; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D016853:Muromonab-CD3; D011241:Prednisone / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D011241:Prednisone; D008775:Methylprednisolone